AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06614647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker
Description: IG patients will receive the following intervention at 3, 12, 24, and 36 months post-surgery:~1) Recurrence risk stratification by ctDNA analysis of blood samples:~a) Only if ctDNA becomes positive, will imaging be performed. b) If ctDNA is positive, but recurrent disease is not detected by imaging or clinical and endoscopic evaluation, the patient will be referred back to intensified ctDNA measurements repeated every 4 months until either ctDNA becomes negative or recurrence is confirmed by subsequent imaging.
Study NCT06614647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)
Description: 2) Collection and analyses of ePROMs to identify whether patients suffer from organ-specific late effects or biopsychosocial late effects and monitor of health related quality of life and the impact of late adverse effects hereon.
Study NCT06614647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic treatment of organ-specific late effects and/or biopsychosocial late effects
Description: 3) When needed, standardized treatment for organ-specific late effects according to newly published national guidelines at specialized centers. Further, online cognitive behavioral therapy is offered to patients suffering from severe biopsychosocial late effects.
Study NCT06614647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital care-guide for long-term follow-up after cancer treatment
Description: Use of a digital care-guide from study inclusion to guide the patient trough the follow-up program, in the form of a personalized smart phone app.
Study NCT06685185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-1063
Description: NNC0363-1063 will be administered subcutaneously.
Study NCT06685185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT06685185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Insulin degludec will be administered subcutaneously.
Study NCT05436054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picoprep
Description: 200 patients will be randomised to this arm
Study NCT05436054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenvu
Description: 200 patients will be randomised to this arm
Study NCT05700721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given by PO
Study NCT05700721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by IV (vein)
Study NCT04174560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.4 Challenge Pool
Description: Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
Study NCT06697535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061
Description: Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.
Study NCT06697535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Glucocorticoids
Description: Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.
Study NCT06697535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Glucocorticoids
Description: Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.
Study NCT06697535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Glucocorticoids
Description: Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
Study NCT06697535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucocorticoids
Description: Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
Study NCT06698211 — intervention group
Intervention type: DRUG
Intervention: Posaconazole tablet
Description: Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined. Once patients developed GI GVHD, first line therapy and second line treatment will be reviewed according to the condition, besides which the Posaconazole plasma concentration would be detected again on the first, third and fifth day after onset of GI GVHD symptoms to monitor the impact of GI GVHD on the Posaconazole plasma concentration.
Study NCT06697054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy with either ICG or carbon dye injection to cervix
Description: Either laparatomy or laparoscopy wil be performed to detect sentinel node stained with either ICG or carbon dye injected to cervix. A hemipelvis in which a sentinel is not found will be subjected to full lymphadenectomy.
Study NCT06697938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative SBRT for the Primary Lesion of Breast Cancer
Description: SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion >3 cm, GTV 30Gy/5F.
Study NCT06696664 — intervention group
Intervention type: DRUG
Intervention: PEG-IFN-α
Description: chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks
Study NCT06697249 — intervention group
Intervention type: OTHER
Intervention: Analysis of postoperative CT scans checking for the feasibility of transcatheter valve-in-root implantation
Description: CT scans of patients after biological root replacement and root repair were assessed with the 3mensio Software (Aortic valve package, 3mensio 10.1, Pie Medical Imaging. Before carrying out the measurements, markers for alignment of the aortic root and ascending aorta were placed manually. The annular area was measured for both groups. In patients after biological root replacement the area of the annulus was defined as the ring of the initial aortic valve prosthesis. Coronary buttons were measured at their lowest and highest point to define partial or full position below the valve level and the general button size. For assessment of the annular-to-coronary distance, the lower edge of the coronary button was chosen. VTC was assessed after root replacement in patients who had at least one coronary partially under the level of the valve. For this measurement a virtually inserted valve was placed in the bioprosthetic frame.
Study NCT06697626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin, B-vitamins and vitamin D
Description: Intervention twice daily with:~10g chicory inulin 100µg folic acid 5µg vitamin B12 5mg vitamin B6 2.5mg riboflavin 5µg vitamin D
Study NCT06697626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: A twice daily placebo drink with similar energy content but without the additional nutrient provision
Study NCT06696885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile based video games and task based training
Description: The experimental group received a mobile-based applications for 20 minutes and tasks-based training for 20 minutes per day (a total of 40 minutes), 6 days a week for 17 weeks. The time between each game was divided accordingly to work on improving hand function. The games and tasks were divided into three broad categories, Easy, Moderate, Difficult. Each category is applied for 6 weeks
Study NCT06697795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Assisted Hypnotherapy
Description: Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic neck pain.
Study NCT06697795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
Study NCT06697080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells
Study NCT05859997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRL-301
Description: Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
Study NCT06221046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream D
Description: Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 2 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 2 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment
Study NCT06221046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 1 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 1 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after the skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment
Study NCT05574374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker
Study NCT05574374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202202
Description: Clopidogrel Bisulfate
Study NCT05574374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202203
Description: Proton pump inhibitor
Study NCT06500871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium
Description: NSAID
Study NCT06500871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: NSAID
Study NCT05979818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Description: 10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Study NCT05830916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antiphospholipid antibodies
Description: Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells
Study NCT05202236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
Study NCT05174052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
Study NCT05174052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 1 blinded capsule of placebo drug dosed once daily
Study NCT06135597 — intervention group
Intervention type: OTHER
Intervention: This is a blood test without regarding to intervention nor diagnostic tests
Description: This is a blood test without regarding to intervention nor diagnostic tests
Study NCT05433298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: Administration of advanced cell product
Study NCT05433298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer's lactate, albumin and heparin solution
Study NCT06410781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shockwave
Description: Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.
Study NCT06410781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
Study NCT06410781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
Study NCT05491005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total diet replacement
Description: Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
Study NCT05491005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth
Description: All follow-up through an eHealth application and video meetings.
Study NCT05491005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face
Description: All follow-up through face-to-face meetings.
Study NCT05979818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Study NCT05979818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Study NCT05616455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionibacterium Acnes
Description: Application of the gel every 12 hours for 40 days
Study NCT05616455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyceryl trinitrate
Description: Application of the gel every 12 hours for 40 days
Study NCT05447416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy - HBOT
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
Study NCT05447416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Hypoxic Training - IHT
Description: Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
Study NCT04112199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIV201 continuous infusion
Description: BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
Study NCT05953987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic combined with diaphragmatic breathing exercise (EXDB)
Description: The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
Study NCT05953987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise (EX)
Description: The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
Study NCT05953987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sedentary control (CON)
Description: The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
Study NCT05759806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nephronyx system (Perfuser)
Description: Temporary deployment of the Nephronyx system (Perfuser)
Study NCT04399564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: temporary hemodialysis catheters
Description: Vascular access using temporary vs.long-term hemodialysis catheters
Study NCT04399564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term hemodialysis catheters
Description: long-term hemodialysis catheters
Study NCT05791318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYD222
Description: Monoclonal antibody
Study NCT05010694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH35 Tablet
Description: GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
Study NCT06390553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Task-Oriented Virtual Reality Application with Crowd Simulation
Description: Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
Study NCT06390553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Parkinson Rehabilitation
Description: Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
Study NCT06390553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Parkinson Rehabilitation
Description: Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
Study NCT05879640 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep education
Description: Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
Study NCT05992233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual wavelength low level laser
Description: Application of double wavelength low level laser to the related area after tooth extraction.